Maxim Group Reaffirms “Buy” Rating for Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics (NASDAQ:KZIA)‘s stock had its “buy” rating reiterated by research analysts at Maxim Group in a report released on Wednesday,Benzinga reports. They presently have a $15.00 target price on the stock. Maxim Group’s target price suggests a potential upside of 53.22% from the company’s current price.

Kazia Therapeutics Trading Up 2.6%

Shares of KZIA stock opened at $9.79 on Wednesday. Kazia Therapeutics has a twelve month low of $2.86 and a twelve month high of $79.00. The stock has a 50 day moving average of $4.00 and a 200 day moving average of $7.55.

Institutional Trading of Kazia Therapeutics

A hedge fund recently bought a new stake in Kazia Therapeutics stock. Barclays PLC purchased a new stake in Kazia Therapeutics Limited (NASDAQ:KZIA) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 120,000 shares of the company’s stock, valued at approximately $212,000. Barclays PLC owned about 2.38% of Kazia Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 30.89% of the company’s stock.

About Kazia Therapeutics

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.